Takeda Pharmaceutical Company Limited



Media Contact: Corporate Communications Department Tel +81-3-3278-2037

News Release

Takeda Voluntarily Adopts International Financial Reporting Standards (IFRS)

Osaka, Japan, May 9, 2013 – Takeda Pharmaceutical Company Limited ("Takeda", TSE: 4502) announced that it has resolved at a meeting of the Board of Directors held today that, as of the fiscal year ending March 31, 2014 (fiscal year 2013, "FY2013"), it will voluntarily adopt the International Financial Reporting Standards (IFRS) for consolidated financial statements, in place of the Japanese Generally Accepted Accounting Principles (J-GAAP) previously adopted.

As part of its strategy toward the realization of sustainable growth, Takeda acquired Nycomed A/S in 2011, a company which had a strong business base in emerging markets. This acquisition allowed Takeda to expand its global sales channels, and we have decided to adopt IFRS based on our intention to further strengthen our global business activities in the future. The adoption of IFRS will enable easier comparison of financial information with pharmaceutical companies in the U.S. and Europe, will increase financing options, and will allow Takeda to unify accounting procedures across the Takeda group.

The following table shows the estimated consolidated financial forecasts for FY2013 calculated under IFRS, reflecting the major differences (*1) between J-GAAP and IFRS accounting.

Billion yen

	J-GAAP (A)	IFRS (B)	Difference (B-A)
Net Sales	1,590.0	1.590.0	_
Operating Income	140.0	155.0	+15.0
Net Income	95.0	115.0	+20.0

^(*1) For details of the major differences between J-GAAP and IFRS, please refer to slides 15 and 23 of the supplementary material, "Consolidated Financial Results of FY2012, Consolidated Financial Forecasts for FY2013 and Guidance for Sustainable Growth", from today's announcements. http://www.takeda.com/investor-information/results/

Our anticipated schedule toward the voluntary adoption of IFRS at the end of FY2013 is as follows:

Fiscal year	r	Disclosure items	Reporting accounting
			standards
FY2012	Year end	Summary of financial statements	J-GAAP (*2)
FY2013	From 1 st quarter	Quarterly summary of financial statements	J-GAAP (*3)
	to 3 rd quarter		
	Year end	Summary of financial statements, Consolidated	IFRS (*4)
		financial statements, Annual securities report	

^(*2) Provisional figures for FY2013 forecasts under IFRS to be disclosed as a reference in supplementary materials

^(*3) Provisional figures for FY2013 quarterly results under IFRS to be disclosed as a reference in supplementary materials

^(*4) FY2013 year end results under J-GAAP to be disclosed as a reference